XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

February 1, 2024

https://www.globenewswire.com/news-release/2024/02/02/2822581/0/en/XORTX-Files-an-Amended-and-Restated-Prospectus-Supplement-for-the-Offering-of-Units.html

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ:XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has filed an amended and restated prospectus supplement for its previously announced offering of for aggregate gross proceeds of up to $2 million. Under the amended and restated prospectus supplement, the size of the offering is increased by $2 million to up to $4 million.

Read more at globenewswire.com

Related news for (XRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.